CI&T and Natura Leverage Artificial Intelligence to Make the Digital Environment More Inclusive and Efficient for up to 1.8 Million Consultants
Focusing on diversity and enhancing user experience, the initiative has positively impacted 1.8 million Natura and Avon Beauty Consultants, offering more intuitive, accessible journeys tailored to the varying navigation needs of these partners. Over 60 product, technology, and design experts from Natura and CI&T collaborated in the creation of an inclusive and lasting digital transformation, where it is possible to adapt and identify new needs over time.
For CI&T, AI allows for the identification of less obvious barriers, real-time suggestions for improvements, and the automation of recurring checks on digital platforms. CI&T employees with disabilities directly participated in the creation and validation of interfaces.
'Involving individuals with disabilities in development is not just a matter of representation—it is what makes the initiative more practical and connected to the reality of its users. These experiences guide more empathetic and effective solutions. This is undoubtedly a great example of using artificial intelligence in favor of human needs,' says Cinthia Oliveira, global head of ESG at CI&T.
The work has evolved based on three main fronts: technical diagnosis, active participation of people with disabilities, and continuous training of teams. On the technical side, tools like CI&T Flow, CI&T's proprietary GenAI platform, utilize AI to assess digital interfaces according to the international Web Content Accessibility Guidelines (WCAG) and broader A11Y best practices, Additionally, empathy workshops and training for leadership and design teams contribute to strengthening a more conscious and sensitive culture towards diversity.
About CI&T
CI&T (NYSE: CINT) is a global technology transformation specialist for 100+ large enterprises and fast growth clients. CI&T brings a 30-year track record of helping clients navigate change to deliver accelerated business impact, with deep expertise across AI, strategy, customer experience, software development, cloud services, data and more. CI&T's proprietary AI platform, CI&T FLOW boosts team productivity, ensuring fast, efficient, and scalable delivery of world-class solutions. Operating globally with over 7,400 professionals across 10 countries, CI&T delivers cutting-edge solutions to drive success for its clients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Thompson Davis Reaffirms Their Buy Rating on GXO Logistics (GXO)
Thompson Davis analyst maintained a Buy rating on GXO Logistics on August 8 and set a price target of $65.00. The company's shares closed last Friday at $50.33. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In addition to Thompson Davis, GXO Logistics also received a Buy from J.P. Morgan's Brian Ossenbeck in a report issued on August 7. However, on the same day, Loop Capital Markets maintained a Hold rating on GXO Logistics (NYSE: GXO). The company has a one-year high of $63.33 and a one-year low of $30.46. Currently, GXO Logistics has an average volume of 1.29M.
Business Insider
3 hours ago
- Business Insider
‘Time to Double Down,' Says Top Investor About Novo Nordisk Stock
It has been a rough few seasons for Novo Nordisk (NYSE:NVO) investors, as the company's share price has tumbled some 60% over the past twelve months. Though Novo Nordisk remains the dominant player in the burgeoning GLP-1 market, worries over a complex regulatory environment, lowered guidance, and increasing competition, among other concerns, have whittled away some of its support. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. And yet, the company's Q2 2025 earnings call last reflected rising sales of 18% during the first half of the year, increased operating profits of 29% for the first six months as well, and advancements with strategic R&D initiatives including an oral weight loss medicine. The market responded with a warmth that has been missing, and NVO's share price has increased by double digits since the earnings call. Top investor James Foord thinks a turnaround is indeed beckoning. 'The recent stock correction presents a rare long-term buying opportunity, supported by a strong pipeline, manufacturing expansion, and international momentum,' asserts the 5-star investor, who is among the top 2% of TipRanks' stock pros. The investor notes that the company succeeded in delivering strong numbers in Q2, with GLP-1 drugs leading the way. While sales for Ozempic – used to treat Type 2 diabetes – jumped by 35%, the Wegovy weight loss drug saw its sales increase by 67%. And it's not just the North American market which is gaining steam, points out Foord. Japan experienced a 91% increase in GLP-1 drugs in Q2. It is this dominance in the GLP-1 market which gives Foord plenty of bullish confidence in NVO going forward – especially as Wegovy aims for a 2026 tablet form. 'Novo has shown superior performance in their latest pill version of Wegovy versus Lily, and this is very encouraging,' adds Foord. With the company spending billions of dollars to increase production capabilities, including in North Carolina, and the potential for GLP-1 drugs to be used for additional morbidities such as Alzheimer's and cardiovascular disease, the investor predicts NVO is on the road to recovery. 'With new facilities coming online, oral drugs in development, and global demand still exploding, I see NVO not only rebounding but potentially doubling in the next few years,' concludes Foord. 'I'm buying more.' No surprise here, Foord is rating NVO a Strong Buy. (To watch James Foord's track record, click here) Though slightly more tempered, Wall Street is also optimistic about NVO. With 2 Buy ratings and 3 Holds, NVO enjoys a Moderate Buy consensus rating. Its 12-month average price target of $71.75 has an upside north of 40%. (See NVO stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
3 hours ago
- Yahoo
Fidelis Insurance Holdings' (NYSE:FIHL) Shareholders Will Receive A Bigger Dividend Than Last Year
Fidelis Insurance Holdings Limited (NYSE:FIHL) will increase its dividend on the 26th of September to $0.15, which is 50% higher than last year's payment from the same period of $0.10. This makes the dividend yield 2.4%, which is above the industry average. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Fidelis Insurance Holdings' Projections Indicate Future Payments May Be Unsustainable Estimates Indicate Fidelis Insurance Holdings' Could Struggle to Maintain Dividend Payments In The Future Fidelis Insurance Holdings' Future Dividends May Potentially Be At Risk While it is great to have a strong dividend yield, we should also consider whether the payment is sustainable. Fidelis Insurance Holdings is not generating a profit, but its free cash flows easily cover the dividend, leaving plenty for reinvestment in the business. We generally think that cash flow is more important than accounting measures of profit, so we are fairly comfortable with the dividend at this level. EPS is forecast to rise very quickly over the next 12 months. Assuming the dividend continues along recent trends, we could see the payout ratio reach 222%, which is on the unsustainable side. View our latest analysis for Fidelis Insurance Holdings Fidelis Insurance Holdings Doesn't Have A Long Payment History It's not possible for us to make a backward looking judgement just based on a short payment history. This doesn't mean that the company can't pay a good dividend, but just that we want to wait until it can prove itself. Fidelis Insurance Holdings Could Grow Its Dividend The company's investors will be pleased to have been receiving dividend income for some time. Fidelis Insurance Holdings has impressed us by growing EPS at 8.0% per year over the past five years. Even though the company isn't making a profit, strong earnings growth could turn that around in the near future. As long as the company becomes profitable soon, it is on a trajectory that could see it being a solid dividend payer. In Summary Overall, this is probably not a great income stock, even though the dividend is being raised at the moment. The company is generating plenty of cash, which could maintain the dividend for a while, but the track record hasn't been great. We would probably look elsewhere for an income investment. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. As an example, we've identified 1 warning sign for Fidelis Insurance Holdings that you should be aware of before investing. Is Fidelis Insurance Holdings not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
